<DOC>
	<DOC>NCT00366080</DOC>
	<brief_summary>The purpose of this study is to assess the effectiveness and safety of the drug GSK189254 in treating patients with narcolepsy.</brief_summary>
	<brief_title>Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy</brief_title>
	<detailed_description />
	<mesh_term>Narcolepsy</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine H3 Antagonists</mesh_term>
	<criteria>Inclusion criteria: Narcolepsy patients Body mass index between 18 32 kg/m2 Females may be of child bearing or nonchild bearing potential. Agreement to refrain from driving or operating heavy machinery for the duration of the study. Must be able to withdraw from medication for the treatment of daytime sleepiness and must not be living on their own. Exclusion criteria: History or presence of major psychiatric disorder or depression. History of significant head trauma in the previous 12 months. Participation in a clinical trial in the previous 3 months. Patient has significant and recent (within 1 year) history of drug or alcohol abuse. Patient is pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GSK189254 H3 Histamine Narcolepsy</keyword>
</DOC>